Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Yingmei Feng and Ronghua Jin.
Connection Strength

1.584
  1. Quantification of SARS-CoV-2 antigen levels in the blood of patients with COVID-19. Sci China Life Sci. 2021 07; 64(7):1193-1196.
    View in: PubMed
    Score: 0.229
  2. Lower Circulating Interferon-Gamma Is a Risk Factor for Lung Fibrosis in COVID-19 Patients. Front Immunol. 2020; 11:585647.
    View in: PubMed
    Score: 0.226
  3. Interferon-Induced Transmembrane Protein 3 Genetic Variant rs12252-C Associated With Disease Severity in Coronavirus Disease 2019. J Infect Dis. 2020 06 16; 222(1):34-37.
    View in: PubMed
    Score: 0.222
  4. Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines. Cell Res. 2021 07; 31(7):732-741.
    View in: PubMed
    Score: 0.059
  5. Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development. Signal Transduct Target Ther. 2021 03 27; 6(1):134.
    View in: PubMed
    Score: 0.059
  6. Longitudinal Profiling of Antibody Response in Patients With COVID-19 in a Tertiary Care Hospital in Beijing, China. Front Immunol. 2021; 12:614436.
    View in: PubMed
    Score: 0.058
  7. COVID-19 immune features revealed by a large-scale single-cell transcriptome atlas. Cell. 2021 04 01; 184(7):1895-1913.e19.
    View in: PubMed
    Score: 0.058
  8. Early Use of Corticosteroid May Prolong SARS-CoV-2 Shedding in Non-Intensive Care Unit Patients with COVID-19 Pneumonia: A Multicenter, Single-Blind, Randomized Control Trial. Respiration. 2021; 100(2):116-126.
    View in: PubMed
    Score: 0.058
  9. Early Detection of Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies as a Serologic Marker of Infection in Patients With Coronavirus Disease 2019. Clin Infect Dis. 2020 11 19; 71(16):2066-2072.
    View in: PubMed
    Score: 0.057
  10. Downregulated Gene Expression Spectrum and Immune Responses Changed During the Disease Progression in Patients With COVID-19. Clin Infect Dis. 2020 11 19; 71(16):2052-2060.
    View in: PubMed
    Score: 0.057
  11. Immune suppression in the early stage of COVID-19 disease. Nat Commun. 2020 11 17; 11(1):5859.
    View in: PubMed
    Score: 0.057
  12. Comparison of qualitative and quantitative analyses of COVID-19 clinical samples. Clin Chim Acta. 2020 Nov; 510:613-616.
    View in: PubMed
    Score: 0.056
  13. Preliminary Exploration of the Cause of Liver Disorders During Early Stages in COVID-19 Patients. Front Med (Lausanne). 2020; 7:501.
    View in: PubMed
    Score: 0.056
  14. Longitudinal COVID-19 profiling associates IL-1RA and IL-10 with disease severity and RANTES with mild disease. JCI Insight. 2020 07 09; 5(13).
    View in: PubMed
    Score: 0.056
  15. The inhibition of IL-2/IL-2R gives rise to CD8+ T cell and lymphocyte decrease through JAK1-STAT5 in critical patients with COVID-19 pneumonia. Cell Death Dis. 2020 06 08; 11(6):429.
    View in: PubMed
    Score: 0.055
  16. A Novel Scoring System for Prediction of Disease Severity in COVID-19. Front Cell Infect Microbiol. 2020; 10:318.
    View in: PubMed
    Score: 0.055
  17. Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells. Cell. 2020 07 09; 182(1):73-84.e16.
    View in: PubMed
    Score: 0.055
  18. High-dimensional immune profiling by mass cytometry revealed immunosuppression and dysfunction of immunity in COVID-19 patients. Cell Mol Immunol. 2020 06; 17(6):650-652.
    View in: PubMed
    Score: 0.055
  19. Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia. Aging Dis. 2020 Apr; 11(2):216-228.
    View in: PubMed
    Score: 0.054
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.